Observational Study
. 2018 Apr 1;144(4):349-359. doi: 10.1001/jamaoto.2017.3406. Association of Survival With Shorter Time to Radiation Therapy After Surgery for US Patients With Head and Neck CancerAffiliations
AffiliationsItem in Clipboard
Observational Study
Association of Survival With Shorter Time to Radiation Therapy After Surgery for US Patients With Head and Neck CancerJeremy P Harris et al. JAMA Otolaryngol Head Neck Surg. 2018.
. 2018 Apr 1;144(4):349-359. doi: 10.1001/jamaoto.2017.3406. AffiliationsItem in Clipboard
AbstractImportance: Shortening the time from surgery to the start of radiation (TS-RT) is a consideration for physicians and patients. Although the National Comprehensive Cancer Network recommends radiation to start within 6 weeks, a survival benefit with this metric remains controversial.
Objective: To determine the association of delayed TS-RT with overall survival (OS) using a large cancer registry.
Design, setting, and participants: In this observational cohort study, 25 216 patients with nonmetastatic stages III to IV head and neck cancer were identified from the National Cancer Database (NCDB).
Exposures: Patients received definitive surgery followed by adjuvant radiation therapy, with an interval duration defined as TS-RT.
Main outcomes and measures: Overall survival as a function of TS-RT and the effect of clinicopathologic risk factors and accelerated fractionation.
Results: We identified 25 216 patients with nonmetastatic squamous cell carcinoma of the head and neck. There were 18 968 (75%) men and 6248 (25%) women and the mean (SD) age of the cohort was 59 (10.9) years. Of the 25 216 patients, 9765 (39%) had a 42-days or less TS-RT and 4735 (19%) had a 43- to 49-day TS-RT. Median OS was 10.5 years (95% CI, 10.0-11.1 years) for patients with a 42-days or less TS-RT, 8.2 years (95% CI, 7.4-8.6 years; absolute difference, -2.4 years, 95% CI, -1.5 to -3.2 years) for patients with a 43- to 49-day TS-RT, and 6.5 years (95% CI, 6.1-6.8 years; absolute difference, -4.1 years, 95% CI, -3.4 to -4.7 years) for those with a 50-days or more TS-RT. Multivariable analysis found that compared with a 42-days or less TS-RT, there was not a significant increase in mortality with a 43- to 49-day TS-RT (HR, 0.98; 95% CI, 0.93-1.04), although there was for a TS-RT of 50 days or more (HR, 1.07; 95% CI, 1.02-1.12). A significant interaction was identified between TS-RT and disease site. Subgroup effect modeling found that a delayed TS-RT of 7 days resulted in significantly worse OS for patients with tonsil tumors (HR, 1.22; 95% CI, 1.05-1.43) though not other tumor subtypes. Accelerated fractionation of 5.2 fractions or more per week was associated with improved survival (HR, 0.93; 95% CI, 0.87-0.99) compared with standard fractionation.
Conclusions and relevance: Delayed TS-RT of 50 days or more was associated with worse overall survival. The multidisciplinary care team should focus on shortening TS-RT to improve survival. Unavoidable delays may be an indication for accelerated fractionation or other dose intensification strategies.
Conflict of interest statementConflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
FiguresFigure 1.. Association of Delay From Surgery…
Figure 1.. Association of Delay From Surgery to Radiation (T S-RT ) With Overall Survival
A, Kaplan-Meier…
Figure 1.. Association of Delay From Surgery to Radiation (TS-RT) With Overall SurvivalA, Kaplan-Meier estimates of overall survival according to a TS-RT of 42 days or less, 43 to 49 days, or 50 days or more. The adjusted hazard ratio (HR) was determined from a Cox multivariable regression model with a TS-RT of 42 days or less as the reference. B, Adjusted HR for mortality by TS-RT modeled as a continuous variable with a restricted cubic spline with 3 knots. A 42-day TS-RT was used as the reference. Shading indicates the 95% CI for HR estimates.
Figure 2.. Subgroup Effects of Covariates With…
Figure 2.. Subgroup Effects of Covariates With Significant Interactions With T S-RT
Adjusted hazard ratio for…
Figure 2.. Subgroup Effects of Covariates With Significant Interactions With TS-RTAdjusted hazard ratio for mortality according to a TS-RT of 43 to 49 days or 50 days or more compared with 42 days or less varied by disease site. TS-RT indicates time from surgery to the start of radiation.
Figure 3.. Association of Accelerated Fractionation With…
Figure 3.. Association of Accelerated Fractionation With Overall Survival (OS)
Kaplan-Meier estimates of OS according…
Figure 3.. Association of Accelerated Fractionation With Overall Survival (OS)Kaplan-Meier estimates of OS according to standard (<5.2 average fractions per week) or accelerated (≥5.2 average fractions per week) fractionation. The adjusted hazard ratio was determined from a Cox multivariable regression model with standard fractionation as the reference.
Similar articlesLavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Lavaf A, et al. Cancer. 2008 Feb 1;112(3):535-43. doi: 10.1002/cncr.23206. Cancer. 2008. PMID: 18076014
George JR, Yom SS, Wang SJ. George JR, et al. JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1118-26. doi: 10.1001/jamaoto.2013.4539. JAMA Otolaryngol Head Neck Surg. 2013. PMID: 24051518
Kao J, Lavaf A, Teng MS, Huang D, Genden EM. Kao J, et al. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):362-70. doi: 10.1016/j.ijrobp.2007.09.058. Epub 2007 Dec 31. Int J Radiat Oncol Biol Phys. 2008. PMID: 18164833
Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Bourhis J, et al. Lancet. 2006 Sep 2;368(9538):843-54. doi: 10.1016/S0140-6736(06)69121-6. Lancet. 2006. PMID: 16950362 Review.
Duckett KA, Kassir MF, Nguyen SA, Brennan EA, Chera BS, Sterba KR, Halbert CH, Hill EG, McCay J, Puram SV, Jackson RS, Sandulache VC, Kahmke R, Osazuwa-Peters N, Ramadan S, Nussenbaum B, Alberg AJ, Graboyes EM. Duckett KA, et al. Otolaryngol Head Neck Surg. 2024 Nov;171(5):1265-1282. doi: 10.1002/ohn.835. Epub 2024 Jun 6. Otolaryngol Head Neck Surg. 2024. PMID: 38842034
Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Xiao R, et al. Head Neck. 2019 Oct;41(10):3551-3563. doi: 10.1002/hed.25873. Epub 2019 Jul 11. Head Neck. 2019. PMID: 31294897 Free PMC article.
Kim MS, Sheridan M, Rajaraman M, Hollenhorst H, Caissie A, Mahmoud-Ahmed A, Lamond N, Snow S, Corsten M, Mark Taylor S, Trites JRB, Rigby MH, Bullock M, Wilke D. Kim MS, et al. Clin Transl Radiat Oncol. 2023 Aug 8;42:100668. doi: 10.1016/j.ctro.2023.100668. eCollection 2023 Sep. Clin Transl Radiat Oncol. 2023. PMID: 37608964 Free PMC article.
Jin MC, Shi S, Wu A, Sandhu N, Xiang M, Soltys SG, Hiniker S, Li G, Pollom EL. Jin MC, et al. Neurooncol Pract. 2020 Jun 18;7(6):626-635. doi: 10.1093/nop/npaa034. eCollection 2020 Dec. Neurooncol Pract. 2020. PMID: 33312677 Free PMC article.
Renslo B, Sawaf T, Virgen CG, Farrokhian N, Yu KM, Somani SN, Penn J, Ziegler A, Gan GN, Kakarala K, Shnayder Y, Bur AM, Sykes KJ. Renslo B, et al. Otolaryngol Head Neck Surg. 2023 Oct;169(4):928-937. doi: 10.1002/ohn.270. Epub 2023 Jan 29. Otolaryngol Head Neck Surg. 2023. PMID: 36939526 Free PMC article.
Fareed MM, Galloway TJ. Fareed MM, et al. Cancers Head Neck. 2018 Dec 19;3:11. doi: 10.1186/s41199-018-0038-4. eCollection 2018. Cancers Head Neck. 2018. PMID: 31093364 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3